Get the Stockscreener App
8.83
7.97%
-0.765
After Hours:
8.83
Transcode Therapeutics Inc stock is traded at $8.83, with a volume of 59,562.
It is down -7.97% in the last 24 hours and up +60.25% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$9.595
Open:
$9.49
24h Volume:
59,562
Relative Volume:
1.07
Market Cap:
$8.39M
Revenue:
-
Net Income/Loss:
$-40.36M
P/E Ratio:
-0.1815
EPS:
-48.648
Net Cash Flow:
$-21.40M
1W Performance:
+2.56%
1M Performance:
+60.25%
6M Performance:
+10.24%
1Y Performance:
-1.89%
1-Day Range:
$8.48
$10.69
1-Week Range:
$7.296
$10.69
52-Week Range:
$3.82
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.83 | 9.12M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Price to earnings forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to book forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to sales forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (RNAZ) Movement - Stock Traders Daily
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps - TipRanks
Nasdaq review delays TransCode (NASDAQ: RNAZ) vote on preferred conversion - Stock Titan
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - TradingView
TransCode Therapeutics, Inc. Actuals & Estimates (BOATS:RNAZ) - TradingView
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RNAZ Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Discipline and Rules-Based Execution in RNAZ Response - Stock Traders Daily
TransCode Highlights Progress of Lead RNA Cancer Therapeutic - TipRanks
Transcript : TransCode Therapeutics, Inc.Special Call - marketscreener.com
TransCode Therapeutics posts investor presentation detailing Phase 1a safety, Phase 2a plan and $12.8M cash - TradingView
TransCode Therapeutics (NASDAQ: RNAZ) furnishes new investor presentation via Form 8-K - Stock Titan
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com
RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
RNAZ: Introducing RNA Therapeutics - Yahoo Finance
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Sahm
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan
(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -
TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia
TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):